舒利迭配伍孟鲁斯特治疗中重度慢性阻塞性肺病稳定期60例随访观察  

Seretide joint Montelukast treatment moderate and severe chronic obstructive pulmonary disease follow-up observation of 60 cases

作　　者：吕景云[1] 朱莹[1] 

机构地区：[1]北京大学医院内科,北京100871

出　　处：《陕西医学杂志》2011年第1期45-47,共3页Shaanxi Medical Journal

摘　　要：目的:探讨舒利迭配伍孟鲁司特治疗中重度慢性阻塞性肺病(COPD)的临床疗效。方法:将74例中重度COPD患者随机分为对照组、舒利迭组、舒利迭加孟鲁斯特组,分别给予氨茶碱、舒利迭及舒利迭配伍孟鲁司特治疗。于治疗前及治疗中每年评估6m in步行试验,肺功能检查及各组间年住院人次,并追踪观察4年,对比各组效果。结果:单纯使用舒利迭及舒利迭配伍孟鲁司特6m in步行试验,肺功能改善指标明显高于单纯使用氨茶碱组(P<0.05),年住院人次明显低于单纯使用氨茶碱组(P<0.05)。结论:舒利迭配伍孟鲁司特治疗中重度COPD稳定期具有较好的疗效。Objective： Discussion clinical efficacy of moderate to severe chronic obstructive pulmonary disease（COPD） with Seretide joint Montelukast treatment.Methods： 74 patients with moderate to severe COPD were randomly divided into the aminophylline group,Seretide group and Seretide joint Montelukast group.The three groups were given treatment with aminophylline,Seretide and Seretide joint Montelukast.Before and after treatment,The three groups were assessed with 6min walk test,pulmonary function test and the number of annual inpatients of the groups was counted,the three groups were followed 4 years,and then the results were compared.Results：Comparison between the three groups,the pulmonary function of the Seretide group and the Seretide joint Montelukast group with 6min walk test were significantly improved（P0.05）,the annual inpatients of the pulmonary function of the Seretide group were significantly decreased（P0.05）.Conclusion：Seretide is a moderate to severe COPD in stable and effective treatment modalities;Seretide joint Montelukast in the treatment of moderate to severe COPD in stable synergistic effect.

关 键 词：肺疾病 慢性阻塞性/药物疗法 肾上腺素能 β激动剂/治疗应用 糖皮质激素类/治疗应用 

分 类 号：R563.3[医药卫生—呼吸系统]